Drug intelligence / Profile preview

hMPV_Y low dose vaccine

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

hMPV_Y low dose vaccine is an investigational human metapneumovirus (hMPV) vaccine candidate developed by GSK. It was evaluated as part of a Phase 1/2 clinical trial (NCT04141540) designed to assess the safety, reactogenicity, and immunogenicity of various hMPV and RSV/hMPV combination vaccine formulations in younger adults (18-49 years) and older adults (60-80 years). The 'Y' designation refers to a specific investigational formulation of the hMPV vaccine, administered at a low dose via intramuscular injection. The vaccine aims to elicit a protective immune response against hMPV, a significant cause of viral respiratory tract infections, particularly in infants, the elderly, and immunocompromised individuals.

02

Targets

HMPV F (Human metapneumovirus fusion protein)TCR (T-cell receptor (TCR) recognizing human metapneumovirus (hMPV) fusion (F) protein-derived peptides presented by major histocompatibility complex (MHC))

Beyond the preview

Go deeper on hMPV_Y low dose vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hMPV_Y low dose vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call